Endogenous Sphingolipid Signaling Pathway Implicated in the Action of Croton Membranaceus on the Prostate Gland in BPH Patients

Overview

Journal Medicines (Basel)

Specialty Pharmacology

Date 2017 Nov 22

PMID 29156544

Authors

George Awuku Asare

Yvonne Anang

Daniel K Afriyie

Brodrick Yeboah Amoah

Bernice Asiedu

Derek Doku

Hannah Serwah Ocansey

Nana Yaw Odei Danso

Prince Tekpor

Sarah Osam

Affiliations

Soon will be listed here.

Abstract

Croton membranaceus extract has apoptotic effects on BPH-1 cells. This study determined if the apoptotic effects were created through the ceramide pathway. The study was a follow-up to a previous observational study of 30 histologically confirmed patients with benign prostatic hyperplasia (BPH) who were on ethanolic extract at 20 mg t.i.d orally for 3 mo. Thereafter, total and free prostate-specific antigen (PSA), lipid profile plus Apo lipoprotein A and B, ceramide/Sphingophospho-kinase 1 (SphK1) and 2 (SphK2), sphingosine lyase (SPL), the cytotoxic adducts of oxidative stress 4-hydroxy-2-nonenal (4HNE) and malondialdehyde (MDA), were determined. Total and free PSA were significantly ( < 0.05) different after treatment. Apo lipoprotein A was significantly different ( = 0.024). The SphK1/SphK2 ratio reduced significantly ( = 0.049). Furthermore, SPL, ceramide, and MDA increased significantly after treatment ( = 0.05, = 0.004, and = 0.007, respectively). A weak positive correlation was found between high-density lipoprotein (HDL) cholesterol and SphK1, and HDL and ceramide before treatment ( = 0.036, r = 0.3826; = 0.018, r = 0.4286, respectively. uses the ceramide pathway by modulating the SphK1/SphK2 ratio and increasing SPL to generate oxidative stress and consequently apoptosis.

References

Eto M, Bennouna J, Hunter O, Lotze M, Amoscato A . Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. Int J Urol. 2006; 13(2):148-56. DOI: 10.1111/j.1442-2042.2006.01249.x. View

Colombini M . Ceramide channels and their role in mitochondria-mediated apoptosis. Biochim Biophys Acta. 2010; 1797(6-7):1239-44. DOI: 10.1016/j.bbabio.2010.01.021. View

Samsel L, Zaidel G, Drumgoole H, Jelovac D, Drachenberg C, Rhee J . The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate. 2004; 58(4):382-93. DOI: 10.1002/pros.10350. View

Afriyie D, Asare G, Bugyei K, Lin J, Peng J, Hong Z . Mitochondria-dependent apoptogenic activity of the aqueous root extract of Croton membranaceus against human BPH-1 cells. Genet Mol Res. 2015; 14(1):149-62. DOI: 10.4238/2015.January.15.18. View

Le Stunff H, Peterson C, Liu H, Milstien S, Spiegel S . Sphingosine-1-phosphate and lipid phosphohydrolases. Biochim Biophys Acta. 2002; 1582(1-3):8-17. DOI: 10.1016/s1388-1981(02)00132-4. View

Wang J, Fu Y, Kang D . The Association Between Metabolic Syndrome and Characteristics of Benign Prostatic Hyperplasia: A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2016; 95(19):e3243. PMC: 4902470. DOI: 10.1097/MD.0000000000003243. View

Asare G, Afriyie D, Ngala R, Appiah A, Anang Y, Musah I . Shrinkage of Prostate and Improved Quality of Life: Management of BPH Patients with Croton membranaceus Ethanolic Root Extract. Evid Based Complement Alternat Med. 2015; 2015:365205. PMC: 4461762. DOI: 10.1155/2015/365205. View

Gao Y, Gao F, Chen K, Tian M, Zhao D . Sphingosine kinase 1 as an anticancer therapeutic target. Drug Des Devel Ther. 2015; 9:3239-45. PMC: 4484649. DOI: 10.2147/DDDT.S83288. View

Schrecengost R, Keller S, Schiewer M, Knudsen K, Smith C . Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Mol Cancer Res. 2015; 13(12):1591-601. PMC: 4685021. DOI: 10.1158/1541-7786.MCR-14-0626. View

10.

Hait N, Oskeritzian C, Paugh S, Milstien S, Spiegel S . Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta. 2006; 1758(12):2016-26. DOI: 10.1016/j.bbamem.2006.08.007. View

11.

Corona G, Vignozzi L, Rastrelli G, Lotti F, Cipriani S, Maggi M . Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int J Endocrinol. 2014; 2014:329456. PMC: 3943333. DOI: 10.1155/2014/329456. View

12.

Brizuela L, Ader I, Mazerolles C, Bocquet M, Malavaud B, Cuvillier O . First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer. Mol Cancer Ther. 2012; 11(9):1841-51. DOI: 10.1158/1535-7163.MCT-12-0227. View

13.

Traish A, Haider K, Doros G, Haider A . Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction. Horm Mol Biol Clin Investig. 2017; 30(3). DOI: 10.1515/hmbci-2017-0015. View

14.

Parsons J, Bergstrom J, Barrett-Connor E . Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int. 2007; 101(3):313-8. PMC: 2647139. DOI: 10.1111/j.1464-410X.2007.07332.x. View

15.

Afriyie D, Asare G, Bugyei K, Adjei S, Lin J, Peng J . Treatment of benign prostatic hyperplasia with Croton membranaceus in an experimental animal model. J Ethnopharmacol. 2014; 157:90-8. DOI: 10.1016/j.jep.2014.09.007. View

16.

Nickel J, Shoskes D, Roehrborn C, Moyad M . Nutraceuticals in Prostate Disease: The Urologist's Role. Rev Urol. 2008; 10(3):192-206. PMC: 2556486. View

17.

Ryl A, Rotter I, Miazgowski T, Slojewski M, Dolegowska B, Lubkowska A . Metabolic syndrome and benign prostatic hyperplasia: association or coincidence?. Diabetol Metab Syndr. 2015; 7:94. PMC: 4625953. DOI: 10.1186/s13098-015-0089-1. View

18.

Azimi H, Khakshur A, Aghdasi I, Fallah-Tafti M, Abdollahi M . A review of animal and human studies for management of benign prostatic hyperplasia with natural products: perspective of new pharmacological agents. Inflamm Allergy Drug Targets. 2012; 11(3):207-21. DOI: 10.2174/187152812800392715. View

19.

Chapman J, Gouaze-Andersson V, Messner M, Flowers M, Karimi R, Kester M . Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches. Biochem Pharmacol. 2010; 80(3):308-15. PMC: 2883648. DOI: 10.1016/j.bcp.2010.04.001. View

20.

Neubauer H, Pitson S . Roles, regulation and inhibitors of sphingosine kinase 2. FEBS J. 2013; 280(21):5317-36. DOI: 10.1111/febs.12314. View